A Study of ABT-806 in Subjects With Advanced Solid Tumor Types
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Kyle D. Holen, MD
AbbVie
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 54056
Baltimore, Maryland, United States
- Site Reference Id/investigator# 41931
Boston, Massachusetts, United States
- Site Reference Id/investigator# 43422
Tacoma, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2010
- Primary completion
- 30 Nov 2012
- Completion
- 30 Nov 2012
- Last update posted
- 21 Nov 2017
- Registered enrollment
- 49
- Registry id
- NCT01255657
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.